ATOS Atossa Genetics Inc.

0.60
0  -4%
Previous Close 0.62
Open 0.62
Price To book 0.76
Market Cap 2.27M
Shares 3,786,000
Volume 240,769
Short Ratio 5.93
Av. Daily Volume 218,631

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 enrollment to be completed by August 2017.
Fulvestrant
Cuctal carcinoma in situ(DCIS) - invasive breast cancer

Latest News

  1. Atossa Genetics Receives Positive Interim Review From Independent Safety Committee in Phase 1 Endoxifen Dose Escalation Study
  2. Atossa Genetics Enrolls First Cohort of Eight Subjects in Endoxifen Study
  3. Atossa Genetics Closes Public Offering
  4. Seattle breast cancer company stock plummets as it seeks funding to continue operations
  5. Atossa Genetics, Inc. Prices $4,000,000 Public Offering
  6. Atossa Genetics Opens Enrollment in Study of Endoxifen
  7. ATOS: Pure Player in the Breast Care Space
  8. Atossa Genetics Provides Update on its Phase 2 Study of Fulvestrant Administered with its Microcatheter
  9. Atossa Genetics to Present at the 9th Annual Biotech Showcase Conference on January 9, 2017
  10. Atossa Genetics Appoints Jack Cuzick, PhD, FRS, FMedSci, FRCP (hon) as Scientific Advisor
  11. Atossa Genetics Announces Reverse Stock Split
  12. Atossa Genetics to Provide Company Update and Discuss Second Quarter Financial Results on Conference Call on Monday, August 15, 2016
  13. Atossa Genetics Settles Litigation With Besins Healthcare
  14. SeeThruEquity Initiates Coverage on Atossa Genetics, Inc. with a Price Target of $1.15
  15. Atossa Genetics Initiates Additional Drug Development Program
  16. Atossa Genetics to Present at 6th Annual LD Micro Invitational Conference on June 7th, 2016
  17. Atossa Genetics Announces $10 Million At-the-Market Common Stock Purchase Agreement With Aspire Capital Fund, LLC
  18. Atossa Genetics Announces First Quarter 2016 Financial Results and Provides Company Update
  19. Atossa Genetics to Host First Quarter 2016 Financial Results and Company Update Conference Call on Thursday, May 5, 2016